Latest news
Loading news…
Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation.
Ambrx was acquired by Johnson & Johnson in 2024 for $2B.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
79
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- La Jolla, California, United States
Key People at Ambrx
Vice President, Head of Clinical Operations
Director of Human Resources
79
professional contacts at Ambrx
Contact execs at Ambrx →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Ambrx
Loading news…
FAQs about Ambrx
People who checked this page also checked these
Browse the full Acquirezy directory.